The menopausal transition may represent an inflection point for worsening of multiple sclerosis (MS) in women, accordi ...
MS patients who achieve long-term stable disease on disease-modifying therapy may want to stop their medication for varying ...
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...
The FDA issued a boxed warning for anaphylaxis risk linked to Glatiramer acetate and Glatopa, used in MS treatment.
The median wait time between referral and appointment was 34 days, and 18 percent of patients waited more than 90 days, the ...